Zolgensma Cancer Risk: FDA Investigates After 9 Tumour Reports, November 2026
The FDA published a safety communication on 6 November 2026 after nine tumour reports in patients treated with Zolgensma, with insertional oncogenesis confirmed in two cases involving the GLI1 oncogene. There is no recall, and the FDA says benefits continue to outweigh risks for approved uses.











